Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$7.62 USD
+0.73 (10.60%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.53 -0.09 (-1.18%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Aligos Therapeutics, Inc. (ALGS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$108.33 | $175.00 | $75.00 | 1,472.28% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Aligos Therapeutics, Inc. comes to $108.33. The forecasts range from a low of $75.00 to a high of $175.00. The average price target represents an increase of 1% from the last closing price of $6.89.
Analyst Price Targets (3 )
Broker Rating
Aligos Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/19/2024 | H.C. Wainwright & Co. | Ed Arce | Not Available | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/18/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $108.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -2.15 |
ALGS FAQs
Aligos Therapeutics, Inc. (ALGS) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Aligos Therapeutics, Inc. (ALGS) is $108.33. The current on short-term price targets is based on 3 reports.
The forecasts for Aligos Therapeutics, Inc. (ALGS) range from a low of $75 to a high of $175. The average price target represents a increase of $1472.28 from the last closing price of $6.89.
The current UPSIDE for Aligos Therapeutics, Inc. (ALGS) is 1472.28%
Based on short-term price targets offered by three analysts, the average price target for Aligos Therapeutics, Inc. comes to $108.33. The forecasts range from a low of $75.00 to a high of $175.00. The average price target represents an increase of 1% from the last closing price of $6.89.